Probiotic Skincare: Companies, Startups & Research

BASF, Beiersdorf AG and Archer Daniels Midland Company are among the organizations active in probiotic skincare. BASF has patented a cosmetic or dermatological composition containing live probiotic bacteria. Beiersdorf launched Eucerin DERMOPURE CLINICAL PROBIOM8 for acne-prone skin in September 2026. Patent holders also include AOBiome, Symrise AG and Gi Biome.

Seed Health Inc., Azitra and Genome Company are identified as startups working on probiotic skincare. Seed Health has patented compositions and methods using bacterial strains, derivatives and prebiotics to improve the skin microbiome. Azitra develops microbiome-based dermatology treatments, while Genome Company develops Lactobacillus strains for cosmetic compositions.

Jiangnan University, Wroclaw Medical University and Chulalongkorn University are among the research organizations active in the field. Jiangnan University researchers reported topical maltotetraose research related to skin barrier function. Wroclaw Medical University and Chulalongkorn University have studied Lactobacillus rhamnosus formulations, including viability, emulsion stability and potential skin-healing effects.

The grant data records $19,983,045 across 26 grants since 2020. This is the clearest grant-specific total in the available facts. The funding-round entries include projects and transactions that are not clearly tied to probiotic skincare, so their aggregate should not be interpreted as the amount invested in this field.

AOBiome leads the listed patent holders with 9 patents. Symrise AG has 5, while The Regents of the University of California, SNIPR TECHNOLOGIES Ltd, Gi Biome and Igen Biolab each have 4. These counts identify named holders in the patent data; they do not establish the strength or commercial value of the patents.

No: patent activity declined 45.6% in the last 12 months compared with the previous 12 months. Publication activity moved in the opposite direction, rising 19.1% over that comparison period. This contrast suggests continued research interest alongside a slowdown in patenting, though neither trend alone establishes product readiness or market adoption.

Recent developments include a Bifidobacterium animalis subsp. lactis BL-G101 study published in October 2026 and research on postbiotic-loaded emulgels in September 2026. Cosmax BTI and Dankook University also reported validation of a viability-selective PMA-qPCR assay. In September 2026, Beiersdorf launched Eucerin DERMOPURE CLINICAL PROBIOM8, a viable-probiotic approach for acne-prone skin.

The four approaches are live probiotic strains, inactivated cells and lysates, postbiotic metabolites, and prebiotic and synbiotic formulations. Live strains aim to deliver viable microbes but require careful viability control. Inactivated ingredients and metabolites avoid maintaining live cells, while prebiotic and synbiotic products pair supportive substrates with probiotics or related ingredients.

The United States leads the country data with 9,032 documents, followed by the United Kingdom with 2,864 and China with 2,196. Germany and India also have substantial activity, with 2,119 and 2,000 documents respectively. These figures indicate where related activity is recorded, not necessarily where products are manufactured or sold.

Barrier and sensitive-skin care, acne and blemish care, anti-aging and skin rejuvenation, pigmentation and tone, and scalp and hair care are listed applications. Barrier and sensitive-skin care is the largest of these areas in the facts, with 793 documents. Acne and blemish care has 208, while scalp and hair care has 128.